Abstract:Hepatitis B virus (HBV) RNA in serum is a novel biomarker for intrahepatic HBV replication and treatment response. For its proper use, it is essential to identify factors influencing serum HBV RNA level. Using a rapid amplification of complimentary DNA (cDNA) ends (RACE) PCR technique (lower limit of detection [LLD], 800 copies/mL [c/mL]), serum HBV RNA levels were measured in samples of 488 untreated individuals with chronic HBV infection who were eligible to treatment according to currently used recommendations. We explored the association of serum levels of HBV RNA with patient- and virus-associated factors. HBV genotype distribution was 21/10/20/46/3% for A/B/C/D/other. Mean HBV RNA serum level was 5.9 (1.6) log<sub>10</sub> c/mL (hepatitis B e antigen [HBeAg]-positive chronic hepatitis B [CHB], 6.5 [1.2] log c/mL; HBeAg-negative CHB, 4.1 [1.2] log c/mL; P < 0.001). By multivariable linear regression, factors associated with lower HBV RNA level were HBeAg negativity (β = -0.69; P < 0.001), HBV genotypes A (β = -0.13; P = 0.002), B (β = -0.07; P = 0.049), and C (β = -0.61; P < 0.001) in comparison to D, and presence of HBV basal core promoter mutation either alone (β = -0.14; P = 0.001) or in combination with precore mutation (β = -0.22; P < 0.001). Higher serum alanine aminotransferase (ALT) was associated with higher HBV RNA (β = 0.23; P < 0.001). HBV RNA correlated strongly with HBV DNA (HBeAg-pos, r = 0.72; P < 0.001; HBeAg-neg, r = 0.78; P < 0.001) and moderately with quantitative hepatitis B surface antigen (qHBsAg; HBeAg-pos, r = 0.54; P < 0.001; HBeAg-neg, r = 0.19; P = 0.04) and quantitative hepatitis B surface antigen (qHBeAg; r = 0.41; P < 0.001).CONCLUSION: In this multiethnic cohort of 488 untreated individuals with CHB, factors associated with serum HBV RNA level were HBeAg status, serum ALT, HBV genotype, and presence of basal core promotor mutations. For the future use of serum HBV RNA as a clinical marker, it seems mandatory to take these factors into consideration. (Hepatology 2018).

New viral biomarkers for Hepatitis B: Are we able to change practice?

HBcrAgandpgRNAand the therapeutic effect inHBeAg-positive patients receiving anti-viral therapy, baseline serum HBV-RNAis a powerful predictor of response.

Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management

Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers

The development history of new biomarkers for hepatitis B virus infection

HBV Biomarkers and Their Role in Guiding Treatment Decisions

A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook

[Research progress of biomarkers of hepatitis B virus and clinical significance]

[Application of the New Serum Markers in the Research and Development of Innovative Hepatitis B Drugs].

Clinical Significance of Novel Biomarkers to Predict the Natural Course of Hepatitis B Infection.

Novel Biomarkers for the Management of Chronic Hepatitis B Virus Infection

Use of HBV RNA and to predict change in serological status and disease activity in CHB

Characteristics of HBV Novel Serum Markers Across Distinct Phases in Treatment-Naïve Chronic HBV-Infected Patients

Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment

New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection

Immunological biomarker discovery in cure regimens for chronic hepatitis B virus infection

Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection

Predictors of Inflammatory Activity in Treatment-Naive Hepatitis B E-Antigen-negative Patients with Chronic Hepatitis B Infection

Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease

Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study.

Biomarkers of transfusion transmitted occult hepatitis B virus infection: Where are we and what next?